The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression

Gene
Amy S YeeXiaowei Zhang

Abstract

Mechanisms that inhibit cell cycle progression and establish growth arrest are fundamental to tumor suppression and to normal cell differentiation. A complete understanding of these mechanisms should provide new diagnostic and therapeutic targets for future clinical applications related to cancer-specific pathways. This review will focus on the HMG-box protein 1 (HBP1) transcriptional repressor and its roles in cell cycle progression and tumor suppression. The work of several labs now suggests a new pathway for inhibiting G1 progression with exciting possible implications for tumor suppression. Our recent work suggests that the two previously unassociated proteins-the HBP1 transcription factor and the p38 MAP kinase pathway-may now participate together in a G1 regulatory network. Several recent papers collectively highlight an unexpected role and connection of the p38 MAP kinase-signaling pathway in cell cycle control, senescence, and tumor suppression. Together, these initially divergent observations may provide clues into a new tumor suppressive network and spur further investigations that may contribute to new diagnostic and therapeutic targets for cancer.

References

Aug 23, 1996·The Journal of Biological Chemistry·J N LavoieJ Pouysségur
Mar 14, 1997·Science·K IraniP J Goldschmidt-Clermont
May 9, 1998·Proceedings of the National Academy of Sciences of the United States of America·H LiangL Nagarajan
Jul 1, 1998·Annual Review of Biophysics and Biomolecular Structure·C A BewleyG M Clore
Jul 11, 1998·The Journal of Biological Chemistry·T Joneson, D Bar-Sagi
Jul 22, 1998·Molecular and Cellular Biology·H H ShihA S Yee
Sep 4, 1998·Science·T C HeK W Kinzler
Mar 11, 1999·Current Opinion in Genetics & Development·K Macleod
Mar 25, 1999·Genes & Development·J GalceranR Grosschedl
Nov 24, 1999·The EMBO Journal·T ZhumaD Kioussis
Apr 12, 2000·Proceedings of the National Academy of Sciences of the United States of America·S Y LinM C Hung
Sep 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·M ClassonE Harlow
Sep 20, 2000·Proceedings of the National Academy of Sciences of the United States of America·M ClassonE Harlow
Nov 1, 2000·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·N Barker, H Clevers
Nov 1, 2000·Cell·M Bienz, H Clevers
Mar 10, 2001·Experimental Cell Research·M Classon, N Dyson
May 2, 2001·Proceedings of the National Academy of Sciences of the United States of America·R S ArnoldJ D Lambeth
Aug 18, 2001·Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology·H SauerJ Hescheler
Oct 5, 2001·Nature Reviews. Molecular Cell Biology·C J Sherr
Feb 28, 2002·Molecular Cell·Tzu-Ching MengNicholas K Tonks
May 22, 2002·Nature Genetics·Dmitry V BulavinEttore Appella
Jun 26, 2002·The Journal of Biological Chemistry·Kevin PruittChanning J Der
Jun 28, 2002·Cancer Cell·Meera PatturajanDavid Sidransky
Sep 3, 2002·Cancer Cell·Charles J Sherr, Frank McCormick
Dec 18, 2002·Annals of the New York Academy of Sciences·Moshe OrenAvri Ben-Ze'Ev
Feb 13, 2003·Genes to Cells : Devoted to Molecular & Cellular Mechanisms·Hiroaki IwasaFuyuki Ishikawa
Feb 25, 2003·Nature Cell Biology·Anjaruwee S NimnualDafna Bar-Sagi
Mar 22, 2003·Current Opinion in Cell Biology·Toren Finkel
Apr 25, 2003·Trends in Genetics : TIG·Eric VerdinHerbert G Kasler

❮ Previous
Next ❯

Citations

May 28, 2010·Breast Cancer Research and Treatment·Hongling LiRobert Chunhua Zhao
Nov 13, 2007·Journal of Molecular Neuroscience : MN·Jeffery D HainesGuillermina Almazan
Jun 5, 2010·Cell Death and Differentiation·S BorrelliR Mantovani
Mar 3, 2007·Nature Cell Biology·Keith MikuleStephen Doxsey
Feb 3, 2005·Cell Research·Tyler Zarubin, Jiahuai Han
Oct 5, 2011·Nucleic Acids Research·Weibin WangXiaowei Zhang
Sep 13, 2006·Molecular and Cellular Biology·Xiaowei ZhangAmy S Yee
Jan 13, 2006·Annual Review of Pharmacology and Toxicology·Hong Pyo KimAugustine M K Choi
Jul 18, 2009·Arteriosclerosis, Thrombosis, and Vascular Biology·Lampson M FanJian-Mei Li
Jan 23, 2009·International Journal of Biological Sciences·Tina M Thornton, Mercedes Rincon
Nov 21, 2007·Expert Opinion on Therapeutic Targets·Tohru Kiyono
Mar 5, 2016·Analytical Cellular Pathology (Amsterdam)·Yicheng ChenZhigeng Zhang
Apr 21, 2012·Journal of Endodontics·Sandra Helena Penha Oliveira, Vanessa Aparecida Carvalho Santos
Dec 29, 2009·Molecular and Cellular Endocrinology·Katherine A Ewen, Peter Koopman
Dec 29, 2005·International Journal of Cancer. Journal International Du Cancer·Yao-Tsung YehShyng-Shiou F Yuan
Dec 15, 2004·Cancer Letters·Ulrike RennefahrtJakob Troppmair
May 17, 2005·Structure·Cesira de ChiaraAnnalisa Pastore
Mar 10, 2018·Development, Growth & Differentiation·Xiaoping SongYue Pang
Feb 9, 2008·Arteriosclerosis, Thrombosis, and Vascular Biology·Shani ShiloChandan K Sen
Jan 21, 2017·PloS One·Cassy M SpillerPeter Koopman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cell Cycle Pathways

Cell cycle is a complex process regulated by several signal transduction pathways and enzymes. Here is the latest research on regulation of cell cycle and cell cycle pathways.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis